Alkermes plc (ALKS) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

21/25

Growth 5 Margin 4 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

21
Alkermes (ALKS) Q2 2026: Proprietary Product Sales Jump 34% as Orexin Pipeline Expands
July 28, 2026
21
Alkermes (ALKS) Q1 2026: Proprietary Portfolio Sales Surge 38% as Orexin Pipeline Expands
May 05, 2026
15
Alkermes (ALKS) Q4 2025: Avidel Acquisition Adds $315M Lumerize Upside, Shifts Growth Trajectory
February 25, 2026
18
Alkermes (ALKS) Q3 2025: Proprietary Product Sales Jump 16% as Orexin Pipeline Accelerates
October 28, 2025
18
Alkermes (ALKS) Q2 2025: Proprietary Product Sales Jump 14% as Orexin Pipeline Advances
July 29, 2025
19
Alkermes (ALKS) Q1 2025: Orexin Pipeline Momentum Sets Stage for Dual Data Catalysts in H2
July 04, 2025
Alkermes (ALKS) Q3 2024: $200M EBITDA Reset Signals Royalty Cliff, Proprietary Portfolio Now Core Growth Driver
October 24, 2024
Alkermes (ALKS) Q2 2024: Proprietary Portfolio Grows 16% as Orexin Pipeline Advances
July 24, 2024
Alkermes (ALKS) Q1 2024: Proprietary Portfolio Up 9% as Pipeline and Margin Expansion Take Center Stage
May 01, 2024
Alkermes (ALKS) Q4 2023: Proprietary Portfolio Surges 18% as Neuroscience Focus Drives Margin Expansion
February 15, 2024
Alkermes (ALKS) Q4 2023: Proprietary Portfolio Surges 18%, Sharpening Neuroscience Focus
February 15, 2024
20
Alkermes (ALKS) Q3 2023: Proprietary Portfolio Grows 16% as Neuroscience Focus Sharpens
October 25, 2023
Alkermes (ALKS) Q2 2023: Proprietary Portfolio Grows 21%, DTC Spend Hits $28M as Oncology Spin Nears
July 26, 2023
Alkermes (ALKS) Q1 2023: Royalty Win Unlocks $194M, Extending Neuroscience Growth Runway
April 26, 2023
Alkermes (ALKS) Q4 2022: Proprietary Portfolio Now 70% of Revenue as Oncology Spin Accelerates Margin Targets
February 16, 2023

Browse all companies